Randomized trial · people

ARA-290: more corneal nerve fibers at 28 days in sarcoidosis, 4 mg arm

Checked against the paper Randomized trialPublished by PepVault

The takeaway

In this short human trial, ARA-290 increased small nerve fibers in the eye and skin at the 4 mg dose. The evidence that it eases pain more than placebo is less clear.

Kind
Randomized trial
Studied in
People
Number studied
64
Published
2017
Journal
Invest Ophthalmol Vis Sci

What they tested

Does daily cibinetide (ARA-290) regrow small nerve fibers and ease nerve pain in people with sarcoidosis who have lost small nerve fibers?

How the study was done

A phase 2b, randomized, placebo-controlled trial in 64 people with sarcoidosis-linked small nerve fiber loss and nerve pain. They got 1, 4 or 8 mg of cibinetide a day or placebo (a dummy treatment) for 28 days. The main measure was the change in corneal nerve fiber area, which counts nerve fibers in the eye's clear front layer using a special microscope.

A woman in glasses at a kitchen table with a laptop, a mug and her phone

PepVault for iPhone

Taking ARA-290? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

What they found

Compared with placebo, corneal nerve fiber area rose by 697 μm2 in the 4 mg arm (P = 0.012). The 109 μm2 rise in the 1 mg arm and the 431 μm2 rise in the 8 mg arm were not statistically clear. The 4 mg arm also gained regrowing nerve fibers in the skin (GAP-43+ fibers, P = 0.035), and changes in corneal nerve area tracked with changes in skin nerve fibers (ρ = 0.575) and in the 6-minute walk test (ρ = 0.645). Pain improved significantly in all groups. Among people with moderate to severe pain, the 4 mg arm had a placebo-corrected drop described as clinically meaningful (P = 0.157).

What it doesn’t show

It was a small, 28-day trial split across four arms, and only the 4 mg dose clearly beat placebo on the main measure. Nerve fiber counts are stand-in measures for the disease, and the pain result for people with moderate to severe pain came from a subgroup, with P = 0.157.

The paper

Culver et al. Cibinetide Improves Corneal Nerve Fiber Abundance in Patients With Sarcoidosis-Associated Small Nerve Fiber Loss and Neuropathic Pain. Invest Ophthalmol Vis Sci. 2017.

The compound

More studies on ARA-290

Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.

Track it in the app

PepVault for iPhone

Taking ARA-290? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo